Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 13/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494929 | 1.00 | CETP (0.49) | CETPHSD11B1KCNH2PTGS1PTGS2 | |
| SCHEMBL4508290 | 1.00 | CETP (0.49) | CETPHSD11B1KCNH2PTGS1PTGS2 | |
| SCHEMBL11938637 | 0.97 | CETP (0.47) | CETPHSD11B1KCNH2PTGS1PTGS2 | |
| SCHEMBL11938638 | 0.97 | CETP (0.47) | CETPHSD11B1KCNH2PTGS1PTGS2 | |
| SCHEMBL4514631 | 0.93 | CETP (0.42) | CETPHSD11B1GCGR | |
| SCHEMBL4511585 | 0.93 | CETP (0.42) | CETPHSD11B1GCGR | |
| SCHEMBL4511591 | 0.93 | CETP (0.42) | CETPHSD11B1GCGR | |
| SCHEMBL4495991 | 0.92 | CETP (0.57) | CETPHSD11B1KCNH2PTGS1PTGS2 | |
| SCHEMBL4495993 | 0.92 | CETP (0.57) | CETPHSD11B1KCNH2PTGS1PTGS2 | |
| SCHEMBL4499199 | 0.92 | CETP (0.57) | CETPHSD11B1KCNH2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | CYP46A1, CBX3, CDYL | CETP 108/4885HSD11B1 33/4885KCNH2 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.